Each of our portfolio of eight novel, clinical-stage drug candidates has the potential to become a best-in-class or first-in-class treatment for patients.

Our Approach

China has emerged as the second-largest pharmaceutical market in the world, where a growing patient population, significant unmet medical needs, new regulatory reforms and expanding reimbursement are driving demand for high quality, innovative medicines.

About Us

Everest Medicines is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

Our Commitment

We are committed to highest quality, integrity and excellence in how we conduct our business and achieve our goals.

Our Purpose

We are united by our purpose to improve lives with our innovative medicines.

Organization & Management Team

Since our inception in 2017, we have assembled an experienced and visionary management team, and in-licensed eight late-stage drug candidates in four major therapeutic areas: oncology, immunology, cardio-renal disease and infectious disease.

Read More

Rogers Yongqing Luo

Chief Executive Officer

Ian Woo

President and Chief Financial Officer

Neo Xiaofan Zhang

Chief Operating Officer

Jason Brown, Ph.D.

Chief Business Officer

Sunny Xu Zhu

Chief Medical Officer, Infectious Disease

Zhengying Zhu, M.D., Ph.D.

Chief Medical Officer, Internal Medicine

Wei Jennifer Yang, Ph.D

Chief Scientific Officer


 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号